Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

,

IPOs expected to return in 2022 after an increase in SPAC M&As in 2021, says GlobalData

An unforeseen rise in special purpose acquisition company (SPAC) mergers and acquisitions (M&As) as a quicker route for biopharmaceutical companies to enter the public capital markets was witnessed during the COVID-19 pandemic, says GlobalData. However, the leading data and analytics company found that, as economic markets slowly try to rebuild post-pandemic, it is doubtful that […]
Read more

Civica’s insulin initiative will provide strong competition to lower the cost of insulins, says GlobalData

To help combat the nationwide insulin affordability crisis, Civica, a nonprofit generic pharmaceutical company, has launched its Insulin Initiative with the JDRF. The initiative aims to drive affordability and accessibility for all Americans, regardless of insurance status. GlobalData, a leading data and analytics company, found that by entirely changing the production and pricing model, Civica […]
Read more

ARV-110’s Phase II data demonstrates clinical value of PROTACs, a next-generation drug class, says GlobalData

Arvinas’ proteolysis targeting chimeras (PROTACs), bavdegalutamide (ARV-110), which is being investigated as a new therapy for metastatic castration-resistant prostate cancer (mCRPC) in the Phase I/II ARDENT study, has recently shown promising efficacy and safety data for treating mCRPC, providing a huge win for the company, says GlobalData. The leading data and analytics company notes that […]
Read more

Omicron subvariant, BA.2, poses a serious threat to the efficacy of current therapies, says GlobalData

More research is required to determine whether current Omicron treatments are effective against BA.2—the most transmissible of the Omicron subvariants, says GlobalData. The leading data and analytics company notes that vaccines and therapies should be tested specifically against BA.2 to better prepare for challenges that may lay ahead. BA.2 contains numerous unique mutations compared to […]
Read more

Newly approved rare blood cancer drug Vonjo promising for patients with both low and moderate platelet counts, says GlobalData

Not only has CTI BioPharma’s drug Vonjo (pacritinib) already broken new ground by being the first treatment approved for intermediate and high-risk myelofibrosis patients with low platelet counts (below 50×109 per liter of blood), key opinion leaders interviewed by GlobalData note that the drug has promise as a treatment for patients with moderate platelet counts […]
Read more

Chinese immune checkpoint inhibitors to face big hurdles for approval in West, says GlobalData

The development of immune checkpoint inhibitors (ICIs) has been a strong focus of China’s R&D strategy, with these costly agents being used across an increasing number of oncology indications. Multiple domestically developed ICIs have now obtained approval from the National Medical Products Administration, and several more are in the pre-registrational phase, awaiting regulatory approval. However, […]
Read more

European Commission withdraws MA for Pfizer’s Staquis, causing uncertainty for ‘mild to moderate’ AD treatment, says GlobalData

The European Commission (EC) withdrew the marketing authorisation (MA) for Pfizer’s topical phosphodiesterase-4 (PDE4), Staquis (crisaborole) in the EU (known as Eucrisa in the US). This highlights a gap in the market for the treatment of ‘mild to moderate’ atopic dermatitis (AD), one that has yet to be filled by an effective topical therapy. Although […]
Read more

International Women’s Day puts spotlight on Endometriosis, says GlobalData

International Women’s Day commemorates the political, social, economic, and cultural achievements of women throughout history. This important day also creates space to discuss issues that disproportionately affect women—one example of which being gynaecological conditions, such as endometriosis. Despite affecting nearly 10% of women globally, endometriosis lacks proper research, funding, and disease awareness. As a result, […]
Read more

Diagnosed prevalent cases of atopic dermatitis set to reach 42.25 million in 2030 across 7MM, finds GlobalData

The 12-month diagnosed prevalent cases of atopic dermatitis (AD) across the seven major markets (*7MM) are projected to increase from 42.13 million in 2020 to nearly 42.25 million in 2030, with an annual growth rate (AGR) of 0.03%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Atopic Dermatitis – Epidemiology Analysis […]
Read more

Cassava’s simufilam still has further hurdles to face in securing a solid position in the Alzheimer’s disease market, says GlobalData

Cassava Sciences recently announced that the Food and Drug Administration (FDA) had denied a Citizen Petition and associated supplements filed by investors questioning the credibility of positive data from the company’s Phase IIb trial (NCT04079803) of late-stage Alzheimer’s disease (AD) asset, simufilam. Despite this win for the company, simufilam still has further hurdles to face […]
Read more

Novo Nordisk’s Wegovy should successfully overcome supply chain challenges by the end of 2022, says GlobalData

Novo Nordisk’s success in diabetes and obesity drug sales could be impacted by supply chain issues, for the production of its obesity drug Wegovy (semaglutide), unless it can resolve issues with its contract manufacturer says GlobalData. The leading data and analytics company expects Novo Nordisk to successfully overcome the supply challenges surrounding Wegovy in the second half of 2022 […]
Read more

Moderna’s vaccine could help prevent multiple sclerosis, says GlobalData

Following the recent discovery that infection with Epstein-Barr virus increases risk of developing multiple sclerosis (MS) by 32-fold, GlobalData highlights that there are currently 15 Epstein-Barr vaccines in development. Of these, the leading data and analytics company notes that Moderna’s mRNA-1189 is one of the most promising because it is being developed by a successful […]
Read more

AbbVie MDD drug Vraylar will have to compete with low-cost aripiprazole and quetiapine generics, says GlobalData

AbbVie has recently submitted a supplementary new drug application (sNDA) to the FDA for Vraylar (cariprazine) as the adjunctive treatment of major depressive disorder (MDD). However, pricey Vraylar will have to compete with low-cost aripiprazole and quetiapine generics, with competition becoming even fiercer when generic brexpiprazole enters the market in 2026, according to GlobalData, a […]
Read more
1 … 50 51 52 53 54 … 110